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BACKGROUND & AIMS: Eradication of Helicobacter pylori
infection has been reported to reduce the risk of gastric cancer
among asymptomatic individuals in high-risk areas. The
magnitude of beneﬁt of H pylori eradication in populations with
different levels of gastric cancer risk and in different clinical
scenarios is unclear. We performed a systematic review and
meta-analysis of randomized controlled trials and observa-
tional studies to investigate the effects of H pylori eradication
on the incidence of gastric cancer. METHODS: We searched
PubMed, Cochrane Library, and ClinicalTrials.gov, reviewing
titles and abstracts of studies of the effects of eradication of H
pylori infection on risk of gastric cancer, through May 2015. We
also searched bibliographies of included studies, related
reviews, and abstracts presented at Digestive Disease Week.
Twenty-four eligible studies (22 research manuscripts and 2
abstracts) were included in our meta-analysis (715 incident
gastric cancers among a total of 48,064 individuals/340,255
person-years). We assessed the effects, as well as their modi-
ﬁcation by baseline gastric cancer incidence, study design
(randomized trial vs observational study), clinical scenario
(asymptomatic infected individuals vs individuals after endo-
scopic resection of early gastric cancer), demographic charac-
teristics of patients (age and sex), and duration of follow-up.
RESULTS: After adjustment for baseline gastric cancer inci-
dence, individuals with eradication of H pylori infection had a
lower incidence of gastric cancer than those who did not
receive eradication therapy (pooled incidence rate ratio ¼ 0.53;
95% conﬁdence interval: 0.440.64). There was little hetero-
geneity among studies. Baseline gastric cancer incidence
modiﬁed the beneﬁt of H pylori eradication (P ¼ .037 for
interaction); the incidence rate ratio of gastric cancer decreased
in a nonlinear fashion with increasing baseline incidence of
gastric cancer (P ¼ .018, in comparison with the linear model).
The beneﬁt also modestly increased with age (P ¼ .023 for
interaction), but this might be due to correlation between ageand baseline gastric cancer incidence. Eradication provided
signiﬁcant beneﬁt for asymptomatic infected individuals
(pooled incidence rate ratio, 0.62; 95% CI: 0.490.79) and
individuals after endoscopic resection of gastric cancers
(pooled incidence rate ratio, 0.46; 95% CI: 0.350.60). The
beneﬁts of H pylori eradication did not differ with study design,
sex, or follow-up period. CONCLUSIONS: In a systematic review
and meta-analysis, we associated eradication of H pylori infec-
tion with a reduced incidence of gastric cancer. The beneﬁts of
eradication vary with baseline gastric cancer incidence, but
apply to all levels of baseline risk.Keywords: Stomach; Tumor; Risk Factor; Antibiotic.
astric cancer is a major global health threat1–3 andGis the third leading cause of cancer deaths world-
wide causing an estimated >720,000 deaths per year
globally.4 Helicobacter pylori is the most important etio-
logic factor for gastric cancer. H pylori infects approxi-
mately 50% of the global population,4 and it is estimated
that 89% of noncardia gastric cancers, which accounts for
78% of gastric cancer cases, are attributed to H pylori
infection.5,6 H pylori promotes gastric carcinogenesis
through multiple mechanisms. H pylori causes chronic
gastric inﬂammation that can progress to the precancerous
changes of atrophic gastritis and intestinal metaplasia. The
risk of gastric cancer increases in relation to the severity
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H pylori infection can also contribute to gastric mucosal
genetic instability8 by reducing gastric acid secretion
(hypochlorhydria), which can promote the growth of
gastric microbiome that processes dietary components into
carcinogens.7 Eradication of H pylori can result in resolu-
tion of gastric inﬂammation, halt the progression of gastric
mucosal damage, prevent further H pyloriinduced DNA
damage, improve gastric acid secretion, and restore the
microbiome toward normal.8 Because H pylori can be
eradicated with a short course of antibiotic treatment,4
identifying and eradicating H pylori infection could repre-
sent a viable strategy to reduce the enormous disease
burden of gastric cancer.9
There has been increasing interest in mass H pylori
eradication to prevent gastric cancer. However, the beneﬁt
of eradication varies in relation to baseline gastric cancer
risk,10 which varies widely across regions and populations,4
and the extent to which mass H pylori eradication will affect
gastric cancer incidence remains unclear. A recent meta-
analysis combining 6 randomized controlled trials (RCTs)
conducted in asymptomatic infected individuals reported
that H pylori eradication reduced the risk of gastric cancer in
Asians, but the effect might not be generalizable to areas
with a lower incidence rate of gastric cancer.10 However,
that study used the risk (ie, the number of gastric cancer
cases at the end of follow-up divided by the number of in-
dividuals at baseline) for the intervention and comparison
groups in each study to conduct meta-analysis and
expressed the results with risk ratios; this approach does
not take into account differences in follow-up duration and
loss to follow-up. Controversies also exist regarding
whether eradication could still provide protection against
gastric cancer once atrophic gastritis and/or intestinal
metaplasia develops. One RCT conducted in asymptomatic
infected individuals showed that eradicating H pylori
reduced the incidence of gastric cancer only in subjects
without premalignant gastric lesions, but not in those with
atrophic gastritis, suggesting there might be a point of no
return beyond which irreversible molecular changes ren-
ders eradication ineffective or less effective in preventing
progression to cancer.11 However, other RCTs reported that
H pylori eradication could reduce subsequent cancer inci-
dence among individuals with atrophic gastritis12 and those
with early gastric cancer13 who often harbor signiﬁcant
atrophic gastritis and/or intestinal metaplasia in the stom-
ach, arguing against the existence of an absolute point of no
return. Collectively, the magnitude of the beneﬁt of H pylori
eradication among diverse populations, who have different
interaction between host genetic and bacterial virulent fac-
tors and thus harbor different levels of gastric cancer risk,14
remains unclear and the knowledge gap remains wide.
A better understanding of the size of the beneﬁt to be ex-
pected after eradicating H pylori in populations with differing
levels of gastric cancer risk is crucial in deciding whether and
how mass eradication of H pylori should be implemented. We
conducted a systematic review andmeta-analysis of RCTs and
cohort studies conducted in both asymptomatic H pylori car-
riers (ie, primary prevention) and in individuals undergoingendoscopic resection of early gastric cancer (ie, tertiary pre-
vention) to investigate the association between H pylori
eradication and gastric cancer incidence.
Methods
Search Strategy and Selection Criteria
We performed a systematic review in accordance with
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) and MOOSE (Meta-Analysis of Observa-
tional Studies in Epidemiology) guidelines.15 Two investigators
(THC and CKC) independently searched PubMed, Cochrane Li-
brary, and ClinicalTrials.gov and reviewed titles/abstracts for
studies that examined eradication of H pylori and subsequent
risk of gastric cancer until the end of May 2015 without lan-
guage or date restriction by using the terms of Helicobacter
pylori and gastric cancer (see Supplementary Material for the
search strategy). We manually searched bibliographies of
included studies, related reviews, and abstracts presented at
Digestive Disease Week in the United States for additional
references. RCTs and cohort studies that compared individuals
receiving H pylori eradication with those not receiving eradi-
cation with respect to incident gastric cancer or metachronous
recurrence after endoscopic resection of gastric cancer were
eligible for meta-analysis. For studies that assessed other che-
mopreventive interventions in addition to H pylori eradication,
we used the arm that received H pylori eradication alone and
the arm that received placebo or no treatment for meta-
analysis; arms that received other interventions with/without
H pylori eradication were excluded. Studies that did not include
a comparison group (ie, receiving placebo or no treatment) or
evaluated patients who had undergone partial gastrectomy
were excluded from meta-analysis.
Data Extraction and Assessment
for Study Quality
Two investigators (THC and CKC) independently reviewed
full manuscripts of eligible studies and extracted information
into an electronic database, including author, publication year,
country where the study was conducted, study design, sample
size, duration of follow-up, participants’ characteristics, inclu-
sion and exclusion criteria, diagnostic criteria for H pylori
infection, the number of subjects in both intervention and
comparison groups, the number of incident gastric cancers in
both intervention and comparison groups, the modality used
during endoscopic resection for early gastric cancer in the
tertiary prevention trials, and the ﬁnal outcomes. The same
reviewers independently evaluated the risk of bias of included
RCTs with the Cochrane risk of bias tool16 and assessed the
quality of cohort studies with the Newcastle-Ottawa scale.17
Disagreement was resolved by joint review of the manuscript
to reach consensus. When multiple articles for a single study
were found, we used data from the latest publication.
Data Synthesis and Analysis
To account for differences in follow-up durations, we used
incidence rate of gastric cancer for conducting meta-analysis.
Random effects models were used for all meta-analyses to
account for potential heterogeneity among studies. Two
approaches were undertaken for data synthesis. We ﬁrst
May 2016 Helicobacter pylori Eradication and Gastric Cancer Incidence 1115
CL
IN
IC
AL
ATconducted random-effects meta-analysis proposed by DerSi-
monian and Laird with the use of the incidence rate ratio as the
measure of effect size.18 Preplanned subgroup meta-analyses
were undertaken for studies of low, intermediate, and high
baseline incidence of gastric cancer (deﬁned by the tertiles of
incidence rates in the groups not receiving eradication in the
included studies). Subgroup analyses were also conducted with
regard to study designs (ie, RCT or cohort study) and clinical
scenarios (ie, asymptomatic H pylori carriers or patients with
prior endoscopic resection of gastric cancer). We used meta-
regression to evaluate whether incidence rate ratio differed
by tertiles of baseline cancer incidence, study designs, and
clinical scenarios. Potential small study bias was evaluated by
funnel plots and by Egger’s test19 and Begg’s test.20 Heteroge-
neity was evaluated by I2 and Cochran’s Q.21
Second, as traditional meta-analysis can introduce bias
when using continuity corrections for studies with no event in
one of the study arms,22 we also conducted meta-analysis using
generalized linear mixed models.23 We used random effect
Poisson regression to model the effect of H pylori eradication on
gastric cancer incidence with the number of cases as the
outcome and the person-year as the offset in the model. The
study by treatment interaction was included as the random
effect in the regression model.
We further evaluated whether the effect of H pylori eradi-
cation on subsequent gastric cancer incidence was modiﬁed by
the baseline gastric cancer incidence with the inclusion of
interaction terms between the treatment and baseline gastric
cancer incidence as ﬁxed effects in the model; baseline gastric
cancer incidence was treated as a continuous variable in the
analysis because the incidence rate was apparently a contin-
uous variable and categorizing a continuous variable might
result in loss of information.24 This approach also enabled us to
assess how the beneﬁt of eradication changed linearly/non-
linearly with varying baseline gastric cancer incidence. If sig-
niﬁcant interaction between treatment and baseline gastric
cancer incidence existed, the relation between incidence rate
ratio and baseline cancer incidence was modeled using
restricted cubic splines with 3 knots to explore potential
nonlinear relationship as well as the threshold value for a
signiﬁcant treatment effect. Likewise, we examined whether
study design (ie, RCT vs cohort), clinical scenario (ie, asymp-
tomatic infected individuals vs individuals after endoscopic
resection of early gastric cancer), demographic characteristics
(ie, age and sex), and follow-up duration would modify the
effect of H pylori eradication on subsequent gastric cancer
incidence. All P values were 2-sided, and P < .05 was consid-
ered to indicate statistical signiﬁcance.
For sensitivity analysis, we ﬁrst excluded studies that were
published as abstracts. Second, we repeated the analysis with
the exclusion of each study in turn to evaluate whether any
study had excessive inﬂuence on the results of our meta-
analysis.
All meta-analyses were conducted using the statistical
software package Stata 14 (StataCorp, College Station, TX).Results
Literature Search
We identiﬁed 8,061 articles for review of title and
abstract (Figure 1). After initial screening, full text ofpotentially eligible articles was retrieved for detailed
assessment. Twenty-four eligible studies including 22 full-
text manuscripts and 2 abstracts were included for meta-
analysis, with 715 incident gastric cancers among a total
of 48,064 individuals/340,255 person-years. Study charac-
teristics and outcomes are summarized in Table 1. Among
included studies, 14 studies11,25–37 were conducted in
asymptomatic infected individuals and 10 studies13,38–46 in
individuals who had undergone endoscopic resection of
early gastric cancers. Most studies were conducted in Asia;
only 2 studies were conducted in other regions (Colombia
and Finland).25,36 Mean age at enrollment ranged from 42 to
63 years in all studies except a cohort study30 from Japan
that focused on elderly patients (68 to 90 years). Except
2 studies26,28 reported in abstract form, all included
studies were considered as high or moderate quality
(Supplementary Tables 1 and 2).Traditional Random-Effects Meta-Analysis
Among all 24 studies, gastric cancer developed in 253
of 20,484 infected individuals who received eradication
therapy, compared with 462 of 27,580 infected individuals
who did not receive antiH pylori treatment. No signiﬁ-
cant small study bias was found (Begg’s test, P ¼ .17, and
Egger’s test, P ¼ .18; Supplementary Figure 1). Individuals
receiving eradication had a lower incidence rate of gastric
cancer than those without eradication; the pooled inci-
dence rate ratio was 0.54 (95% conﬁdence interval [CI]:
0.460.65] without signiﬁcant heterogeneity (I2 ¼ 0%;
P ¼ .67) (Figure 2).
The baseline gastric cancer incidence (ie, incidence rate
of gastric cancer in the group not receiving eradication) in
each study varied widely from 34.3 to 10,256.4 per 100,000
person-years (Table 1). All studies of the intermediate and
the highest tertiles of incidence were conducted in Asia. Of
the 8 studies in the highest tertile of baseline incidence, 1
study assessed the preventive effect of eradication in in-
dividuals with gastric adenoma at baseline,30 and others
evaluated cancer incidence after endoscopic resection of
early gastric cancer. As shown in Figure 2, in studies cate-
gorized into the intermediate (314.3 to 2,941.2 per 100,000
person-years) and highest tertiles (2,970.0 to 10,256.4 per
100,000 person-years) of baseline gastric cancer incidence,
individuals receiving antiH pylori treatment had a signiﬁ-
cantly lower incidence of gastric cancer as compared with
those who did not receive treatment; the pooled incidence
rate ratios were 0.49 (95% CI: 0.380.64) and 0.45 (95%
CI: 0.320.64), respectively. The beneﬁt of H pylori eradi-
cation was nonsigniﬁcant in studies of the lowest tertile of
gastric cancer incidence (34.3253.6 per 100,000 person-
years); the pooled incidence rate ratio was 0.80 (95% CI:
0.561.15).
Meta-regression analysis reafﬁrmed that the quantita-
tive beneﬁt of H pylori eradication was greater in studies
with higher baseline incidence rates of gastric cancer.
Using studies of the lowest tertile of baseline incidence as
reference, the pooled incidence rate ratios for eradication
vs noneradication were reduced by 43.5% (95% CI:
Figure 1. Flow chart of literature search and selection.
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1.7%61.4%) in the intermediate tertile, respectively.
Subgroup analyses according to different clinical sce-
narios (Figure 3) showed that the quantitative beneﬁt of
eradication seemed greater among individuals after endo-
scopic resection of gastric cancers (pooled incidence rate
ratio ¼ 0.46; 95% CI: 0.350.60) than among asymptomatic
infected individuals (pooled incidence rate ratio ¼ 0.62,
95% CI: 0.490.79), but the difference was not signiﬁcant
(P ¼ .12 by meta-regression). The beneﬁt of H pylori erad-
ication was comparable in RCTs and cohort studies, with
pooled incidence rate ratios of 0.60 (95% CI: 0.440.81)
and 0.52 (95% CI: 0.410.64), respectively (P ¼ .44 by
meta-regression).Mixed-Effect Poisson Regression Meta-Analysis
Results of the mixed-effect Poisson regression meta-
analysis were similar with those of the traditional meta-
analyses. Individuals who received H pylori eradication
had a lower incidence of gastric cancer than those who did
not receive eradication therapy; the pooled incidence rate
ratio was 0.53 (95% CI: 0.440.64) with little heteroge-
neity across studies (Table 2, model 1). Interaction ana-
lyses showed that baseline gastric cancer incidence
signiﬁcantly modiﬁed the beneﬁt of eradication (model 2);
the incidence rate ratio of gastric cancer decreased in a
nonlinear fashion with rising baseline incidence rate (P ¼
.018 in comparison with linear model) (Figure 4). The
upper 95% CI of incidence rate ratio for eradication
decreased to <1 when baseline gastric cancer incidence
exceeded 150 per 100,000 person-years, and the inci-
dence rate ratio continued to decrease with rising
baseline incidence up to around 1,200 per 100,000
person-years and then stabilized. With exclusion of 2studies25,39 that did not provide information on age of
participants, age also seemed to modestly modify the
beneﬁt of eradication (model 5, P value interaction ¼
.023); the incidence rate ratio decreased by 3% (95% CI:
0%5%) with every 1-year increase in the median age of
participants. However, the interaction between age and
eradication became nonsigniﬁcant (P value interaction ¼
.25) when interaction between eradication and baseline
incidence was also entered into the model; therefore, the
impact of age on the effect of eradication might be due to
the fact that studies with older patients tended to have
higher baseline gastric cancer incidence. The beneﬁt
conferred by H pylori eradication did not differ by study
design, clinical scenario, the percentage of male subjects,
or follow-up duration (model 3, 4, 6 or 7). No material
difference in results was noted in prespeciﬁed sensitivity
analyses, and no individual study had excessive inﬂuence
on the summary estimate.Discussion
This meta-analysis is the ﬁrst to evaluate the association
between H pylori eradication and the incidence of gastric
cancer across different levels of baseline gastric cancer risk
and in different clinical scenarios. Our results support the
concept that H pylori eradication effectively reduces the
incidence of gastric cancer, and the magnitude of the pro-
tective effect is greater among individuals with higher
baseline gastric cancer risk.
In the 2 previous meta-analyses that also evaluated the
effect of H pylori eradication on gastric cancer prevention,
the estimated relative risks were closer to 1 and had wider
CIs (relative risk ¼ 0.65, 95% CI: 0.430.9847 and relative
risk ¼ 0.66; 95% CI: 0.460.95,10 respectively) compared
with our estimates. Several reasons might explain why our
meta-analysis showed greater beneﬁt with better preci-
sion. The 2 previous meta-analyses summarized only 5
and 6 RCTs, respectively. Furthermore, those RCTs were
conducted in asymptomatic carriers; most of those in-
dividuals likely belonged to the subgroup with the lowest
gastric cancer risk among all H pyloriinfected in-
dividuals.11,25,26,28,29 Therefore, the evidence base in
previous meta-analyses was relatively limited. Secondly,
previous meta-analyses used risk ratios to conduct meta-
analysis, but risk ratios did not account for differences
in follow-up durations between/within studies and could
yield less precise pooled estimates. Our pooled rate ratio
(0.63; 95% CI: 0.500.81) for asymptomatic carriers
(baseline incidence from 68.7 to 314.3 per 100,000
person-years in the included RCTs) was similar to those
from previous meta-analyses, but with a narrower conﬁ-
dence interval. We were also able to identify that H pylori
eradication provided even greater beneﬁt among high-risk
individuals. Taken together, our meta-analysis has a wider
evidence base and greater statistical power with more
precise estimates; therefore, our results should better
reﬂect the full spectrum of the potential beneﬁt of
implementing mass H pylori eradication for gastric cancer
prevention.
Table 1.Characteristics of Studies Evaluating the Effect of Helicobacter Pylori Eradication on the Primary and Tertiary Prevention of Gastric Cancer
First author, Year Country Mean age, y Male, %
Mean
follow-up, mo
Treatment group Comparison group
Total, n GC, n
GC incidence,
/100,000 PY Total, n GC, n
GC incidence (baseline
incidence), /100,000 PY
Studies on asymptomatic infected
individuals (primary prevention)
RCT
Correa, 200025 Colombia 51.1 46.0 72 491 3 101.8 485 2 68.7
Wong, 200411 China 42.2 54.0 90 817 7 114.2 813 11 180.4
Saito, 200526 Japan NA NA 48 379 2 131.9 313 3 239.6
You, 200627 China 50.7 51.4 176 1130 34 205.1 1128 52 314.3
Zhou, 200828 China 53.4 47.8 120 276 2 72.5 276 7 253.6
Wong, 201229 China 52.9 46.1 60 255 3 235.3 258 1 77.5
Cohort study
Saito, 200030 Japan 79.2 54.7 24 32 0 0 32 4 6250.0
Take, 200731 Japan 50 88.7 47 953 9 241.1 178 4 573.8
Takenaka, 200732 Japan 53.6 71.3 38 1519 6 124.7 288 5 548.2
Ogura, 200833 Japan 62.9 56.5 38 404 6 469.0 304 13 1350.4
Mabe, 200934 Japan 52.9 71.7 67 3781 47 222.6 352 9 457.9
Yanaoka, 200935 Japan 49.8 99.9 112 473 5 117.3 3656 55 156.7
Kosunen, 201136 Finland 55.3 50.0 121 3650 11 29.0 11638 37 34.3
Lee, 201337 Taiwan 49.2 45.8 60 4121 15 72.8 4121 16 77.7
Studies on individuals after endoscopic
resection of early GC (tertiary prevention)
RCT
Fukase, 200813 Japan 68 76.5 36 272 9 1102.9 272 24 2941.2
Choi, 201438 Korea 60 67.7 36 444 10 750.8 457 17 1240.0
Cohort study
Uemura, 199739 Japan 69 72 36 65 0 0 67 6 2985.1
Nakagawa, 200640 Japan NA NA 24 356 8 1123.6 2469 129 2612.4
Shiotani, 200841 Japan 66 84 33 80 9 4090.9 11 1 3305.8
Maehata, 201242 Japan 69 72.3 36 177 15 2824.9 91 13 4761.9
Seo, 201343 Korea 62 67.6 27 61 6 4371.6 13 3 10,256.4
Kwon, 201444 Korea 61 67.1 40 214 10 1401.9 69 10 4347.8
Bae, 201445 Korea 63 78.5 56 485 34 1470.0 182 24 2970.0
Kim, 201446 Korea 64 74.3 58 49 2 844.5 107 16 3093.8
GC, gastric cancer; NA, not available; PY, person year.
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Figure 2. Summary incidence rate ratio of gastric cancer associated with H pylori eradication by traditional random-effects
meta-analysis, stratiﬁed by baseline incidence of gastric cancer.
1118 Lee et al Gastroenterology Vol. 150, No. 5
CLINICAL
ATThe novel ﬁnding that the protective effect of H pylori
eradication increased along with increasing gastric cancer
incidence argues against an absolute point-of-no-return
and has important implications. Atrophic gastritis and in-
testinal metaplasia from H pyloriinduced chronic
inﬂammation are the major histologic risk factors for
gastric cancer,7,9,25 underscoring the need to prevent the
occurrence of these precancerous conditions or reduce
subsequent progression to cancer. Three previous
studies11,36,38 suggested that eradicating H pylorimight notreduce the risk of gastric cancer in individuals who has
already developed atrophic gastritis and/or intestinal
metaplasia, but those studies either used premalignant
gastric lesions as surrogate end points36,37 or had only
limited sample size in the subgroups of atrophic gastritis
and/or intestinal metaplasia11; therefore, those studies
might have inadequate statistical power. One meta-analysis
suggested that only subjects with nonatrophic gastritis and
atrophic gastritis could beneﬁt from H pylori treatment on
gastric cancer risk but not subjects with intestinal
Figure 3. Summary incidence rate ratio of gastric cancer associated with H pylori eradication by traditional random-effects
meta-analysis, stratiﬁed by clinical scenario (asymptomatic infected individuals vs individuals after endoscopic resection of
early gastric cancer).
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tably limited by the patchy distribution of intestinal
metaplasia in stomach and the variation in biopsy methods
across studies. Our meta-analysis shows that H pylori
eradication is associated with a reduction of gastric cancer
risk even among high-risk individuals, supporting that H
pylori eradication is beneﬁcial in individuals with atrophic
gastritis and/or intestinal metaplasia. Other lines of evi-
dence also support our ﬁnding. First, almost all gastric
cancer patients have atrophic gastritis and/or intestinal
metaplasia,13 and our meta-analysis showed thateradicating H pylori after endoscopic resection of early
gastric cancer reduced the risk of metachronous cancer by
54%. Second, our population-based mass eradication pro-
gram on Matsu Island of Taiwan found that H pylori
eradication could reduce the severity or reverse the pres-
ence of atrophic gastritis among subjects with premalig-
nant gastric lesions at baseline and reduced gastric cancer
incidence by 25%, from 40.3 to 30.4 per 100,000 person-
years.37
The notable ﬁnding that H pylori eradication confers
greater protection against gastric cancer for individuals
Table 2.Effects of H pylori Eradication and Other Variables on the Incidence Rate of Gastric Cancer
Variables included into modelsa
Eradication
Eradication 
baseline risk
Eradication 
cohort studyb
Eradication 
tertiary preventionc
Eradication 
aged
Eradication 
sexe
Eradication 
follow-up durationf
Model 1
Incidence rate ratio (95% CI) 0.53 (0.440.64)
Model 2
Incidence rate ratio (95% CI) 0.63 (0.500.81)
Interaction P value .037
Model 3
Incidence rate ratio (95% CI) 0.60 (0.440.80)
Interaction P value .340
Model 4
Incidence rate ratio (95% CI) 0.61 (0.480.78)
Interaction P value .097
Model 5
Incidence rate ratio (95% CI) 0.52 (0.430.63)
Interaction P value .023
Model 6
Incidence rate ratio (95% CI) 0.53 (0.440.64)
Interaction P value .103
Model 7
Incidence rate ratio (95% CI) 0.51 (0.420.61)
Interaction P value .064
aStudy-speciﬁc effects are omitted from the table.
bRandomized controlled trial as reference.
cPrimary prevention as reference.
dMedian age in individual studies (Saito et al26 and Nakagawa et al40 excluded due to lack of information).
ePercentage of male subjects in individual studies (Saito et al26 and Nakagawa et al40 excluded due to lack of information).
fMedian follow-up duration in individual studies.
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Figure 4. Nonlinear relation between incidence rate ratio of
gastric cancer associated with H pylori eradication and
baseline gastric cancer incidence. IRR, incidence rate ratio.
Circles indicate incidence rate ratios in individual studies;
size of bubble is proportional to precision (inverse of vari-
ance) of incidence rate ratio. Note that the upper bound of
95% CI starts to decrease <1 and becomes statistically
signiﬁcant when the baseline incidence exceeds the
threshold value of approximately 150 per 100,000 person-
years.
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phenomenon that the risk of gastric cancer increases
exponentially over time in those high-risk individuals.49
Therefore, the difference in subsequent cancer risk be-
tween eradicated and noneradicated groups in an individual
study is likely to be greater if eradication is provided when
the cancer risk has increased to a higher level, and studies
on high-risk individuals might have superior statistical po-
wer than studies on low-risk individuals.50 Indeed, even
with relatively limited sample size and follow-up duration,
the beneﬁt of H pylori eradication was evident in the
included studies that assessed individuals undergoing
endoscopic resection of early gastric cancer, who belonged
to the subset of individuals at the highest risk of gastric
cancer.51
Without effective preventive measures, the current high
incidence of gastric cancer is projected to remain stable or
even increase by 2030.4 The International Agency for
Research on Cancer has indicated the urgent need for
effective preventive measures and for a critical assessment
of H pylori eradication as a preventive strategy.52 Our re-
sults support that mass H pylori screening and eradication
is a viable preventive strategy and should be implemented
in high-risk populations/areas, especially in those with an
incidence rate higher than 150/100,000 person-years.
While we found that the protective effect of H pylori
eradication is less conspicuous in low-incidence in-
dividuals, this ﬁnding does not argue against implementing
H pylori eradication for gastric cancer prevention in low-
incidence populations. Overall, our results clearly show
that eradication protects against gastric cancer; the 95% CI
of the pooled incidence rate ratio crossing one when
incidence rate is <150/100,000 person-years reﬂectslimited statistical power due to smaller effect size and
relative paucity of evidence from low-incidence areas.
Furthermore, H pylori infection can be reliably identiﬁed
with noninvasive methods and eradicated with an overall
success rate >90%53,54 through selecting a regimen with
or without clarithromycin according to the 15%20%
threshold of macrolide resistance in a speciﬁc population.9
In light of the unequivocal beneﬁt of H pylori eradication,
future long-term placebo controlled trials for high-risk
population would be unethical. How H pylori eradication
should be implemented in low-incidence populations/
areas should be further evaluated. For instance, in areas
with intrinsically lower rates of gastric cancer (eg, much of
Europe and North America), there are high-risk pop-
ulations (such as immigrants from high-risk areas) and
thus eradication may need to be focused; simulation
studies have shown that such a strategy would be cost-
effective in the long run.55
Our meta-analysis addresses the limitations of existing
research and has several strengths. Most of previous studies
were underpowered; it is estimated that even in a high-risk
population with an annual incidence rate of 200 per
100,000 person-years, 17,625 individuals per group with a
follow-up duration of 10 years are needed for an RCT to
demonstrate a 50% reduction in gastric cancer incidence
with eradication against placebo.49 Our meta-analysis eval-
uated the association between H pylori eradication and the
incidence of gastric cancer across diverse populations/sce-
narios with different levels of baseline gastric cancer risk,
comprising 20,484 treated and 27,580 untreated individuals
with a total follow-up of 340,255 person-years. The agree-
ment between results from different meta-analytic methods
supports that the results are robust. Our results provide a
more comprehensive and precise estimate of the potential
beneﬁt of implementing H pylori eradication among pop-
ulations at different levels of gastric cancer risk and should
have better generalizability.
Our study also has some limitations. First, all but 2 of
the included studies were conducted in East Asia; there-
fore, whether the results can be extrapolated to other
high-risk areas remains unclear. Second, the presence and
severity of atrophic gastritis and intestinal metaplasia
were not uniformly assessed and reported in the included
studies (ie, they lacked risk stratiﬁcation: Supplementary
Table 3). Therefore, it remains speculative to translate
the magnitude of beneﬁt for subjects with early gastric
cancer to those who have precancerous changes in their
gastric mucosae. Also, we could not further clarify how the
extent and severity of those precancerous conditions
modiﬁes the preventive effect of H pylori eradication.
However, accurate determination of the extent and
severity of atrophic gastritis and intestinal metaplasia
requires endoscopic examination and histologic assess-
ment; routine ascertainment of this information before
eradication is neither feasible nor necessary for most H
pyloriinfected individuals. Third, the outcome assess-
ment may be different between primary and tertiary
prevention studies; the former may obtain the information
from cancer registries (most cancers had clinical
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ATsymptom) while the latter may mainly from endoscopic
surveillance (most cancers were asymptomatic). However,
gastric cancer was characteristic for its rapid progression
with a preclinical detectable phase of only about 1.4
years.56 Without treatment, gastric cancers early in stage
will eventually progress to the symptomatic stage in a
short time period such that the difference between these 2
approaches would be minimal. This interpretation was
also supported by our subgroup analysis that showed no
signiﬁcant difference between the different clinical sce-
narios. Lastly, this meta-analysis was conducted using
summary statistics rather than individual data. The
modest interaction between age and H pylori eradication
may be inﬂuenced by collinearity between age and base-
line gastric cancer incidence. However, there might be
some covariates that could inﬂuence the effect of eradi-
cation, but were not reported and thus could not be
adjusted. Access to and examination of data from indi-
vidual participants should allow further identiﬁcation and
control of potential confounding factors.
In conclusion, our meta-analysis conﬁrms that H pylori
eradication is associated with a reduction of the incidence of
gastric cancer. Although the level of beneﬁt varies, it pre-
sents across all levels of baseline gastric cancer risk. H pylori
eradication may be the most viable strategy for gastric
cancer prevention.Supplementary Material
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Search Strategy
PubMed
(“helicobacter pylori”[MeSH Terms] OR (“helicobacter”
[All Fields] AND “pylori”[All Fields]) OR “helicobacter
pylori”[All Fields]) AND (“stomach neoplasms”[MeSH
Terms] OR (“stomach”[All Fields] AND “neoplasms”[All
Fields]) OR “stomach neoplasms”[All Fields] OR (“gastric”
[All Fields] AND “cancer”[All Fields]) OR “gastric cancer”[All
Fields])
Cochrane Library
Category: helicobacter pylori gastric cancer
(http://onlinelibrary.wiley.com/cochranelibrary/
search)
ClinicalTrials.gov
Category: helicobacter pylori gastric cancer
(https://clinicaltrials.gov/ct2/results?term¼
helicobacterþpyloriþgastricþcancer&Search¼Search)
Digestive Disease Week
Category: helicobacter pylori gastric cancer
(http://www.ddw.org/search?query¼
helicobacterþpyloriþgastricþcancer)
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Supplementary Figure 1. The funnel plot of all 24 eligible
studies does not show asymmetry. Statistical analysis
conﬁrmed no evidence of publication bias with Begg’s test
(P ¼ .17) and Egger’s test (P ¼ .18).
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Supplementary Table 1.Cochrane Risk of Bias Tool Assessment for RCTs
First author, year
Adequate
sequence
generation?
Was treatment
allocation
concealed? Blinding?
Incomplete
outcome
data addressed?
Free of selective
reporting?
Free of
other bias?
Correa, 200025 - - , , - -
Wong, 200411 - - - - - -
Saito, 200528 NA NA - NA - -
You, 200627 - - - - - -
Zhou, 200828 NA NA - NA - -
Wong, 201229 - - - - - -
Fukase, 200813 - NA , - - -
Choi, 201438 - NA , - - -
,, quality measure not fulﬁlled; -, quality measure fulﬁlled; NA, not available.
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Supplementary Table 2.Newcastle-Ottawa Scale for Cohort Study Quality
First author, year
Representative
of the
exposed
cohort
Selection of
the nonexposed
cohort
Ascertainment
of exposure
Demonstration
that outcome
in interest was
not present at
start of the study
Comparability of
cohorts on
the basis of
the design
or analysis
Assessment
of outcome
Was follow-up
long enough for
outcomes to occur?
Adequacy of
follow-up of cohorts
Saito, 200030 + + + + +
Take, 200731 + + + + + +
Takenaka, 200732 + + + + + + +
Ogura, 200833 + + + + + + +
Mabe, 200934 + + + + + +
Yanaoka, 200935 + + + + ++ + + +
Kosunen, 201136 + + + + + + + +
Lee, 201337 + + + + + +
Uemura, 199739 + + + + + + + +
Nakagawa, 200640 + + + + + + + +
Shiotani, 200841 + + + + + + +
Maehata, 201242 + + + + + + +
Seo, 201343 + + + + + +
Kwon, 201444 + + + + ++ + + +
Bae, 201445 + + + + + + + +
Kim, 2014 + + + + + + +
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Supplementary Table 3.Additional Study Information On The Primary And Tertiary Prevention Of Gastric Cancer
First author, year Location
Baseline gastric
mucosal status,
proportion of
atrophic gastritis, %
Baseline gastric
mucosal status,
proportion of
intestinal
metaplasia, %
Baseline gastric
mucosal status,
proportion of
dysplasia, %
Risk ratio of
gastric cancer (95% CI)
Method to
conﬁrm H pylori
Eradication
regimen
Studies on asymptomatic infected
individuals (primary prevention)
RCT
Correa, 200025 Colombia 22.8 67.9 9.2 1.48 (0.258.83) A T
Wong, 200411 China 7.9 28.7 0.6 0.63 (0.251.63) AþD T
Saito, 200526 Japan NA NA NA 0.55 (0.093.27) NA T
You, 200627 China 44.8 33.0 20.1 0.65 (0.431.00) D O
Zhou, 200828 China 49.1 49.5 0 0.29 (0.061.36) AþD T
Wong, 201229 China 22.2 23.4 54.4 3.04 (0.3228.99) C T
Cohort
Saito, 200030 Japan NA NA NA 0.11 (0.011.98) A T
Take, 200731 Japan 100 0 0 0.42 (0.131.35) E T or O
Takenaka, 200732 Japan NA NA NA 0.23 (0.070.74) BþCþDþE and/or A T or O
Ogura, 200833 Japan NA NA NA 0.35 (0.130.90) E or 2 of A, B, C T
Mabe, 200934 Japan NA NA NA 0.49 (0.240.98) D T
Yanaoka, 200935 Japan NA NA NA 0.70 (0.281.75) B T or O
Kosunen, 2011 Finland NA NA NA 0.95 (0.481.86) B NA
Lee, 201337 Taiwan 59.9 31.7 8.4 0.94 (0.46-1.89) C T
Studies on individuals after endoscopic
resection of early gastric cancer
(tertiary prevention)
RCT
Fukase, 200813 Japan 99.6 66.7 NA 0.38 (0.180.79) A or D T
Choi, 201438 Korea 75.5 90.7 NA 0.61 (0.281.31) A or D T
Cohort
Uemura, 199739 Japan NA NA NA 0.08 (0.001.38) B O
Nakagawa, 200640 Japan NA NA NA 0.43 (0.210.87) NA T
Shiotani, 200841 Japan NA NA NA 1.24 (0.178.85) AþB T
Maehata, 201242 Japan 4.2 NA NA 0.59 (0.301.19) One of A, B, C, D T
Seo, 201343 Korea NA NA NA 0.43 (0.121.49) AþCþD T
Kwon, 201444 Korea 97.5 NA NA 0.32 (0.140.74) Two of A, B, D T
Bae, 201445 Korea NA 98 NA 0.53 (0.320.87) One of A, C, D T
Kim, 201446 Korea NA NA NA 0.27 (0.071.14) Two of A, B, D T
A, histology; B, serology; C, 13carbon-urea breath test; D, rapid urease test; E, bacterial culture; T, triple therapy; NA, not available; O, dual therapy.
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